FREMONT, Calif., Feb. 19, 2020 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX) today announced that Mike
Raab, president and chief executive officer of Ardelyx, will
present at the 9th Annual SVB Leerink Global Healthcare
Conference at 3:30 p.m. ET on
Wednesday, Feb. 26, 2020 in New
York City.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor
section of the Ardelyx website at ir.ardelyx.com. A replay of the
webcast will be available on the Ardelyx website for 60 days
following the conference.
About Ardelyx, Inc.
Ardelyx is focused on enhancing
the way people with cardiorenal diseases are treated by developing
first-in-class medicines. Ardelyx's cardiorenal pipeline includes
the Phase 3 development of tenapanor for the treatment of
hyperphosphatemia in patients with CKD on dialysis, and RDX013, a
potassium secretagogue program for the potential treatment of high
potassium, or hyperkalemia, a problem among certain patients with
kidney and/or heart disease. In addition, Ardelyx has received
approval of IBSRELA (tenapanor). To efficiently bring its
treatments to market, Ardelyx is pursuing strategic collaborations
for IBSRELA for IBS-C and tenapanor for hyperphosphatemia in
certain territories. Ardelyx has established agreements with Kyowa
Kirin (formerly known as Kyowa Hakko Kirin) in Japan, Fosun Pharma in China and Knight Therapeutics in Canada.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-301007127.html
SOURCE Ardelyx